Login to Your Account

'Crispr' dough: Genome-editing start-up raises $25M in series A

By Cormac Sheridan
Staff Writer

Thursday, April 24, 2014

Crispr Therapeutics AG, a start-up formed by the co-inventor of the CRISPR/Cas9 genome-editing technology, closed a $25 million series A round.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription